Physiol. Genomics Add DOIs to your references at manuscript stage!
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Physiol. Genomics 39: 56-60, 2009. First published July 7, 2009; doi:10.1152/physiolgenomics.00061.2009
1094-8341/09 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
39/1/56    most recent
00061.2009v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Barbalic, M.
Right arrow Articles by Boerwinkle, E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barbalic, M.
Right arrow Articles by Boerwinkle, E.
Received 3 April 2009; accepted in final form 2 July 2009.
Physiological Genomics 39:56-60 (2009)
1094-8341/09 $8.00 © 2009 American Physiological Society

Kininogen gene (KNG) variation has a consistent effect on aldosterone response to antihypertensive drug therapy: the GERA study

Maja Barbalic 1, Gary L. Schwartz 2, Arlene B. Chapman 3, Stephen T. Turner 2 and Eric Boerwinkle 1,4

1 Human Genetics Center, University of Texas Health Science Center at Houston, Houston, Texas
2 Division of Hypertension, Mayo Clinic, Rochester, Minnesota
3 Division of Nephrology and Hypertension, Emory University, Atlanta, Georgia
4 Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas

Recent experimental and clinical studies suggested that apart from playing an essential role in blood pressure homeostasis, aldosterone is involved in the pathophysiology of cardiovascular and renal diseases by inducing structural changes in the heart, kidney, and vessel wall. The interindividual variation of aldosterone response to antihypertensive treatment is considerable, and is at least partially explained by genetic variation. In this study, we investigated aldosterone response to two antihypertensive drugs—a thiazide diuretic and an angiotensin receptor blocker (ARB). Genetic variations in 50 candidate genes were tested for association with aldosterone response in four independent samples: African American (AA) responders to a diuretic (n = 289), AA responders to an ARB (n = 252), European American (EA) responders to a diuretic (n = 295) and EA responders to an ARB (n = 300). Linear regression was used to test the association with inclusion of age, sex, and body mass index as covariates. The results indicated the existence of one or more variants in the kininogen gene (KNG) that influence interindividual variation in aldosterone response. The significant association was replicated in three of four studied groups. The single nucleotide polymorphism rs4686799 was associated in AA and EA responders to the diuretic (P = 0.04 and P = 0.07, respectively), and rs5030062 and rs698078 were significantly associated in EA responders to the diuretic (P = 0.05 and P = 0.01) and EA responders to the ARB (P = 0.04 and P = 0.02). Although the clinical implication of KNG gene variation to antihypertensive drug response is yet to be determined, this novel candidate locus provides important new insights into drug response physiology.

antihypertensive treatment; candidate genes







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2009 by the American Physiological Society.